Writing a Convincing Dossier on Impurities and Method Validation. Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products
|
|
- Peregrine Cook
- 5 years ago
- Views:
Transcription
1 Writing a Convincing Dossier on Impurities and Method Validation Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products 1
2 Writing a Convincing Dossier on Impurities and Method Validation Last edition: Aktuell 2
3 3
4 Requirements have changed 4
5 What will be presented? Dossier and ethics: who is accountable General principles for a winning dossier Points to consider for impurities Points to consider for method validations Conclusions: Quality dossiers and speed of marketing authorization 5
6 Dossier and Ethics: who is accountable Common goals of the applicant and the agency Rules to be observed (Childress and Beauchamp): - principle of autonomy - principle of non-harm Who is responsible for the dossier and possible harms due to low quality medicines MAH or agency? Who knows best MAE or agency? Who is the moral agent? 6
7 Dossier, Risk Management and Ethics Quality Risk Management ICH Q9 Executive summary for competent authorities and industry 7
8 Dossier, Risk Management and Ethics Empowerment & Flexibility is needed Master complexity and streamline decision making Proactive disclosure build trust and understanding Improve communication through sharing best practice and science based knowledge Convert data into knowledge Integrate corporate ethics into quality risk management (Corporate Policy) 8
9 Dossier, Risk Management and Ethics Corporate Responsibility and Risk Management Risk Corporate Policies Corporate Goals Likelihood Impact Corporate Ethics 9
10 Dossier, Risk Management and Ethics Manage risk to patient, based on science and ethics: Product, process and facility Robustness of Quality System Relevant controls to assess & mitigate risk Moral responsibility of corporation towards patient Level of oversight required commensurate with the level of risk to patient for: Marketing authorisation applications Post-approval change review GMP inspections 10
11 Dossier, Risk M., Quality Systems, Ethics FDA: Quality Systems Approach to Pharmaceutical cgmp Regulations, 9 / 2006 V. Conclusions Quality professionals are aware that good intentions alone will not ensure good products. A robust quality system will promote process consistency by integrating effective knowledge-building mechanisms into daily operational decisions. Specifically, successful quality systems share the following characteristics, each of which has been discussed detail above: - Science-based approaches - Decisions based on an understanding of the intended use of a product - Proper identification and control of areas of potential process weakness - Responsive deviation and investigation systems that lead to timely remediation - Sound methods for assessing and reducing risk - Well-defined processes and products, starting from development and extending throughout the product life cycle - Systems for careful analysis of product quality - Supportive management (philosophically and financially) 11
12 Dossier, Ethics Check Questions to answer before making a decision: Is it legal? Will I be violating either the law or the company policy? Is it risk balanced? Does it account for the risk for the patient and the production risks (is it achievable)? How will it make me fell about myself? Would I give this drug to my wife and my children? Would I feel good if my decision was published in the newspapers, in a journal? 12
13 Ethical question or positive law? Why shall we follow moral rules? (Kant, Bentham, Mill) Philosophy Ethical Question Why shall we document all facts? It s a must It s the law 13
14 14
15 Documentation Point to consider The CTD should be clearly structured All copies must be eligible Pictures and diagrams must have a reasonable size Diagrams must be clearly labelled Units must be included in each table Calculations formulas must be unambiguous Think as a reviewer, who sees this document for the first time 15
16 Night in the black forest? 16
17 Discussion of Results and Conclusions Concise summary of the results Overview tables Final, sound conclusions It is the duty of the MAH to draw the right conclusions and to suggest limits and eventually improvements (commitments) The Agency must look critically at the results and check the logic of the conclusion, but it is not her duty to do the work the MAH has forgotten to do 17
18 CTD Structure: Documents and Granularity A document is defined for a paper submission as a set of pages, numbered sequentially and divided by a tab. A document can be equated to a file for an electronic submission. Granularity : how many CTD sections a document should cover 18
19 Document pagination and segregation If a section contains more than one document, a specific Table of Contents for that section can be included to identify the chronology and titles of the documents contained therein, for example: 19
20 Document pagination and segregation Tab with 3.2.S.4.2 Analytical Procedures Table of Contents, listing the title of Procedure A, Procedure B, Procedure C Tab with 3.2.S.4.2 Procedure A ; Procedure A (i.e. document, page 1-n) Tab with 3.2.S.4.2 Procedure B ; Procedure B (i.e. document, page 1-n) Tab with 3.2.S.4.2 Procedure C ; Procedure C (i.e. document, page 1-n) 20
21 CTD Module 3 Module 3 Note The TOC is only needed in the paper version of the CTD; there is no entry needed for the ectd S Note S S S S S S S S S S S S S S S S S S S S S S S S S S.7.3 N t S P Note P P P.2.1 Note A 3.2.R 3.3 One file per reference Note P P P P P P A A A P.2.2 Note P P P P P P P P P P P P P P P P P P P P P P P P
22 CTD Module 3 Module 3 Note 1 Note 1 : In choosing the level of granularity for this Module the applicant should consider that it will be expected that replacements of complete documents /files are provided in the CTD and ectd when the Documents information rolled is changed at any point up to in this the product's level lifecycle. are not allowed 3.1 The TOC is only needed in the paper version of the CTD; there is no entry needed for the ectd 3.2.S S S S S S S S S S S S S S S S S S S S S.6 substance 3.2.S S S S P Note P P P.2.1 Note S Note S.1 Note 3 : For a drug product supplied with reconstitution diluent(s), the information on the diluent(s) should be provided in a separate part P, as appropriate Module 3 Note 6 : Literature References should be listed in the tables of contents. 3.2.A 3.2.A A R Note One file per reference Note 6 Note 2 : For a drug product containing more than one drug substance, the information requested for part S should be provided in its entirety for each drug 3.2.P.2.2 Note P P P P P P P P P P P P P.4.2 files3.2.p P P P P P P P P P P P P P P.8.1 regional 3.2.P P.8.3 guidance 3.2.A.1 One or multiple documents may be submitted at this level Note 4 : The lower level of headings included in CTD-Q at this point are unlikely to be individual documents or Note 5 : Refer to 22
23 Impurities- Limits (Ph.. Forum Vol 32(5)) Pharmaceutical manufacturer interact with regulatory agencies in developing new drug substances and new drug products,... Establishment of impurity limits in drug substances and drug products should proceed in a rational basis so that everyone involved... can carry on their work in a predictable manner Manufacturer share with regulatory agencies and with the compendia the goal of making available to the public high-quality products that are both safe and efficacious 23
24 Impurities- Limits (Ph.. Forum Vol 32(5)) The ultimate goal is to produce a final drug product of high quality that is safe and efficacious and remains so throughout shelf live. Setting of limits should consider: toxicology of a drug substance containing typical levels of impurities and/or the toxicology of impurities, the route of administration, the daily dose, the target population, the pharmacology of impurities, the source of a drug substance, the duration of therapy, the capability of a manufacturer to produce consistently highquality material 24
25 Impurities- Limits (Ph.. Forum Vol 32(5)) For drug substances and drug products, limits are appropriately set no higher than the level that can be justified and no lower than the level achievable by the manufacturing process and analytical capabilities Where there are no safety concerns, limits should be based on (a) data generated on actual batches of the drug substance or drug product, allowing sufficient latitude to deal with the normal process and analytical variations, and (b) stability characteristics. 25
26 Impurities- Limits (Ph.. Forum Vol 32(5)) Limits for impurities/3-sigma-rule Level of Impurities Validation-/ production-batches for setting the limits! Development Validation/Production Batch No 26
27 Impurities and limits ICH Q3A/B: mean value + 3 Sigma is acceptable Limits should be calculated from typical/validation batches, not from very early batches before optimisation of the process Recommendation: commitment to check the limits eg after the first ten production batches Limits should guarantee, that the process runs always in the validated range 27
28 Impurities- Qualification All impurities above a limit must be qualified: ICH Q3A and Q3B Clear overview over all batches used for preclinical and clinical studies and production/validation batches Eventually syntheses of impurities and special toxicological tests necessary Safe by use what does this mean? 28
29 Impurities- are all detectable? Impurities covered by the substance peak Impurities with high molecular weight: can they possibly exist or can they be excluded? Is there a reasonable mass balance? Heavy metals/catalysts: must there be a specification/test or can they be excluded (validation) Residual solvents: can solvents of early stages be excluded or must there be a test? 29
30 Impurities- are all detectable? 30
31 Impurities Ermer/Miller: Method Validation in Pharmaceutical Analysis Wiley-VCH
32 Impurities and analytical methods Peak purity investigations should be integrated into method development/robustness. Only the absence of evidence, not the evidence of absence can be shown. Variation in chromatographic conditions and /or rechromatography is a simple, sensitive approach Peak shape investigations and DAD must be discussed for small co-eluting substances MS is very sensitive and highly selective, but is also dependent on substance properties 32
33 Impurities and analytical methods Unknown impurities: can they be detected? eg UV-detection/measuring wavelength Are reference substances for all impurities available. How are the response factors? How can unknown impurities be separated into classes like by-products from synthesis, decomposition products Changes of method: comparative impurity profiles of least three batches, new detectable impurities? 33
34 Genotoxic Impurities This is new for the MAH and the agency You are the experts and you must explain There should be a statement, that genotoxic impurities can/can t be present Discussion, why a synthesis without us of genotoxic intermediates/starting materials is not practicable 34
35 35
36 Validation of AM: System Suitability System suitability tests are an integral part of gas and liquid chromatographic methods. They are used to verify that the detection sensitivity, resolution, and reproducibility of the chromatographic system are adequate for the analysis to be done.... The detection sensitivity is a measure used to ensure the suitability of a given chromatographic procedure for the complete detection of the impurities in the Chromatographic purity or Related compounds tests by injecting a volume of a quantitation limit solution equal to that of the Test solution.... at a 0.05% concentration level relative to the amount of drug substance in the Test solution for drug substances, and a 0.1% level relative to the amount of drug substance in the Test solution for drug products. The signalto-noise ratio for the drug substance peak obtained with the quantitation limit solution should be not less than 10 36
37 Validation of AM: System Suitability Must probe, that all impurities above the disregard limit can be detected: limit of quantification Must make shure, that all impurities are separated: Resolution between the peaks that are closest must be shown SST not only for chromatographic methods: particle size, UV-spectra 37
38 Validation of AM: Intermediate Precision Intermediate precision must be done for all analytical methods Intermediate Precision is not robustness For the validation of the intermediate precision of impurities sound limits must be defined before the validation is done (validation protocol is often not include!) 38
39 Validation of AM: Stability Indicating Method A list of all known impurities and decomposition products should be include It should be shown, that all these substances are separated HPLC Peak purity is not sufficient to show that there is no impurity covered by the substance peak. Substance with similar chromophoric groups may have LOD above 0.1% 39
40 Validation of AM: all methods? As a rule all analytical methods must be validated Methods from Ph. Eur. or USP have been validated for monographs of the Ph. only Methods for the following determinations are often not validated: - Water according to Karl Fischer - Particle Size Measurement - Optical Rotation 40
41 Validation of AM: further considerations A summary of the validation results is welcomed, but all results of the validation test must be supplied Eligible, clearly labelled chromatograms must be supplied There must be sound assessment and a final conclusion: usually requirements fulfilled or corrective measurements 41
42 Summary It is the duty of the marketing authorization holder to make sure, that the dossier conforms to the law and the regulations. The agency is not a consulting company! All data should be evaluated by the marketing authorization holder. It is not the duty of the agency to do the work you should do: to analyze the data, to come to the conclusions and make decision Make sure that the dossier does not only conform to the law and the regulations, but do also the ethic check 42
43 43
Impurity Control in the European Pharmacopoeia
Impurity Control in the European Pharmacopoeia Training Session Zagreb, Croatia, 24-25 May, 2018 Dr Ulrich Rose Head of Division European Pharmacopoeia Department, EDQM Agenda Which impurities are controlled?
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationChemical Aspects of Stability Evaluation
Chemical Aspects of Stability Evaluation 8 steps to generating stability data which speaks for itself Alan Doughty Chief Chemist Pty Ltd Aim of a stability trial Obtain data which allows a definitive conclusion
More informationQuestions and answers on the 'Guideline on the limits of genotoxic impurities'
23 September 2010 EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP) Questions and answers on the 'Guideline on the limits of genotoxic impurities'
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationAdopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationConsultation by a notified body on an ancillary medicinal substance integrated in a medical device
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationReflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances
3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management
1 2 3 14 December 2017 EMA/CHMP/ICH/804273/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationGUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION
ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More informationICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP
USP ICH Q2(R1) A Primer GxP cgmp PIC/S SOP ISO 17025 QA/QC LOD/LOQ API EP Validation of Analytical Methods FDA OECD GCP Validation of Analytical Methods Ludwig Huber Contents Preface...............................................
More informationGMPs for Method Validation in Early Development: An Industry Perspective (Part II)
GMPs for Method Validation in Early Development: An Industry Perspective (Part II) Pharmaceutical Technology Volume 36, Issue 7, pp. 76-84 Henrik T. Rasmussen, Vertex Pharmaceuticals, Inc. Donald Chambers,
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationGuideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
More informationCurrent Hotspots during CMC Evaluation a European Regulatory Perspective
www.pei.de Current Hotspots during CMC Evaluation a European Regulatory Perspective CMC Strategy Forum Japan 2018 3-4 December, Tokyo Steffen Gross, Head Section monoclonal - and polyclonal Antibodies
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationGuideline on setting specifications for related impurities in antibiotics
1 2 3 4 14 July 2010 EMA/CHMP/CVMP/QWP/199250/2009 Committee for Medicinal Products for Human Use (CHMP) / Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 Guideline on setting specifications
More informationSPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune
SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved, 2010 1 Contents of the European Pharmacopoeia: nearly 2100 monographs
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationDIFFERING CMC REQUIREMENTS: US AND EU
WHITEPAPER DIFFERING CMC REQUIREMENTS: US AND EU Torsten Schnetgoeke M.Sc. Senior Manager, Regulatory Affairs torsten.schnetgoeke@pharmalex.com Torsten joined PharmaLex in 2015 as a Senior Manager in Regulatory
More informationProposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.
December 2008 Proposals for the Guideline on Classification of Variations Only those variations applicable to the active substance are listed. A variation which is not an extension and whose classification
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationICH Topic Q 3 B Impurities in New Medicinal Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit ICH Topic Q 3 B Impurities in New Medicinal Products Step 4, Consensus Guideline, 6 November 1996 TE FOR GUIDANCE
More informationCleaning and Cleaning Validation of API Plant and Equipment
Regulatory Basis: FDA Quality Systems Regulations Reference: FDA CFR - Code of Federal Regulations Title 21 1 Purpose The purpose of this guideline is: To define the requirements for cleaning plant and
More informationRecent experience in scientific advice and marketing authorisations
Recent experience in scientific advice and marketing authorisations Presented by Brigitte Brake on 16 April 2015 BfArM & BWP, Germany An agency of the European Union Introduction Short introduction to
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationStarting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationBasis for setting acceptance criteria
Basis for setting acceptance criteria Mats Welin, Senior expert Medical Products Agency, BWP Disclaimer: The views presented in the presentation are my own and not necessarily the ones of BWP Fundamentals
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationVaccine Prequalification Dossier
Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
1 2 3 23 June 2016 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the requirements for quality documentation concerning biological investigational
More informationRegulatory requirements for early stage clinical trials with cell-based medicinal products. Christopher A Bravery
Regulatory requirements for early stage clinical trials with cell-based medicinal products Christopher A Bravery cbravery@advbiols.com Opening Remarks Cell-based medicinal products are in themselves diverse,
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationSynthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013
Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs
More informationClinical qualification of specifications - a Regulator s view
Clinical qualification of specifications - a Regulator s view Mats Welin Medical Products Agency, Uppsala, Sweden Disclaimer: The opinions expressed are my own and do not necessarily represent those of
More informationAdvanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming
Advanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming Dr. Jörg Hoffmann / Global Drug Product Governance and CMC Compliance, Merck KGaA (EMD Serono in US) IFPAC Annual Meeting,
More informationRegistration and renewal of the credential certificate for registration
Registration and renewal of the credential certificate for registration 1. Qualification of the applicant: 1.1 Must be a holder of the license to manufacture or import the psychotropic substances of category
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More information1 Analytical Validation within the Pharmaceutical Lifecycle
1 1 Analytical Validation within the Pharmaceutical Lifecycle Phil Nethercote and Joachim Ermer 1.1 Development of Process and Analytical Validation Concepts The concept of validation in the pharmaceutical
More informationGuide to the investigational medicinal product dossier
Guide to the investigational medicinal product dossier Item type Authors Publisher Other Irish Medicines Board (IMB) Irish Medicines Board (IMB) Downloaded 1-May-2018 07:31:12 Link to item http://hdl.handle.net/10147/96980
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options
ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements
More informationUnderstanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation
Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationHow to prepare an application for revision of a CEP
How to prepare an application for revision of a CEP P.Poukens-Renwart, PhD Certification of Substances Division EDQM Summary Validity of a CEP Revision background Types of revisions and examples How to
More informationWirkstoffdokumentation & CEP- Verfahren
Wirkstoffdokumentation & CEP- Verfahren Dr. Wolfgang Herzog AGES PharmMed, Institut Zulassung & Lifecycle Management AGES-Gespräch Am Pulsschlag des Arzneimittelwesens Das Institut LCM 25.11.2010 www.basg.at
More information9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization
USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationSystems-Based Inspections for Cleaning Validation
Systems-Based Inspections for Cleaning Validation FDA DG 230 July 21, 2014 Rockville, MD Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com 1 Cleaning Definition: The process
More informationGuidance for Industry
Draft-t for Implementation Guidance for Industry ANDAs: Impurities in Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationDrug Development - Points to Consider
Drug Development - Points to Consider The Regulator View ד"ר עפרה אקסלרוד מנהלת המכון לביקורת ותקנים של חומרי רפואה והאכיפה אוקטובר 2018 וס. מנהל מערך הרקוחות Keep in mind Know your product Know the regulatory
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationIMPURITIES. Antony Fake API Focal Point, PQTm WHO PREQUALIFICATION TEAM MEDICINES
IMPURITIES Antony Fake API Focal Point, PQTm IMPURITIES PQTm Training Copenhagen, May 2016 1 Introduction This presentation is made with reference to the preparation of an API. This is because the API
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationOASIS DITA Pharma. Initial Meeting 30 July 2009
OASIS DITA Pharma Initial Meeting 30 July 2009 Agenda DITA PCSC Welcome Objectives of today s meeting Introductions Round Robin Expectations of the Group Round Robin Story Boards of Opportunity DITA in
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 31 March 2006 CHMP/QWP/185401/2004 final COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE REQUIREMENTS TO THE CHEMICAL AND PHARMACEUTICAL
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More information